124 related articles for article (PubMed ID: 37392128)
21. Charge convertibility and near infrared photon co-enhanced cisplatin chemotherapy based on upconversion nanoplatform.
Xu J; Kuang Y; Lv R; Yang P; Li C; Bi H; Liu B; Yang D; Dai Y; Gai S; He F; Xing B; Lin J
Biomaterials; 2017 Jun; 130():42-55. PubMed ID: 28364630
[TBL] [Abstract][Full Text] [Related]
22. Synergistic Platinum(II) Prodrug Nanoparticles for Enhanced Breast Cancer Therapy.
Yang CX; Xing L; Chang X; Zhou TJ; Bi YY; Yu ZQ; Zhang ZQ; Jiang HL
Mol Pharm; 2020 Apr; 17(4):1300-1309. PubMed ID: 32058727
[TBL] [Abstract][Full Text] [Related]
23. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
24. Nuclear-Targeting Lipid Pt
Wei D; Fan J; Yan J; Liu C; Cao J; Xu C; Sun Y; Xiao H
J Am Chem Soc; 2024 Jan; 146(1):1185-1195. PubMed ID: 38148611
[TBL] [Abstract][Full Text] [Related]
25. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
26. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
[No Abstract] [Full Text] [Related]
27. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
28. Polypeptide-Based Theranostics with Tumor-Microenvironment-Activatable Cascade Reaction for Chemo-ferroptosis Combination Therapy.
Gao Z; He T; Zhang P; Li X; Zhang Y; Lin J; Hao J; Huang P; Cui J
ACS Appl Mater Interfaces; 2020 May; 12(18):20271-20280. PubMed ID: 32283924
[TBL] [Abstract][Full Text] [Related]
29. An all-in-one biomimetic iron-small interfering RNA nanoplatform induces ferroptosis for cancer therapy.
Huang S; Le H; Hong G; Chen G; Zhang F; Lu L; Zhang X; Qiu Y; Wang Z; Zhang Q; Ouyang G; Shen J
Acta Biomater; 2022 Aug; 148():244-257. PubMed ID: 35709941
[TBL] [Abstract][Full Text] [Related]
30. Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance.
Lin YX; Wang Y; An HW; Qi B; Wang J; Wang L; Shi J; Mei L; Wang H
Nano Lett; 2019 May; 19(5):2968-2978. PubMed ID: 30924343
[TBL] [Abstract][Full Text] [Related]
31. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment.
Li Z; Qiao X; Liu XM; Shi SH; Qiao X; Xu JY
Eur J Med Chem; 2023 Mar; 250():115233. PubMed ID: 36863224
[TBL] [Abstract][Full Text] [Related]
32. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
33. DNA Nanostructures as Pt(IV) Prodrug Delivery Systems to Combat Chemoresistance.
Zhong YF; Cheng J; Liu Y; Luo T; Wang Y; Jiang K; Mo F; Song J
Small; 2020 Sep; 16(38):e2003646. PubMed ID: 32815274
[TBL] [Abstract][Full Text] [Related]
34. SLC7A11/GPX4 Inactivation-Mediated Ferroptosis Contributes to the Pathogenesis of Triptolide-Induced Cardiotoxicity.
Liu X; Chen C; Han D; Zhou W; Cui Y; Tang X; Xiao C; Wang Y; Gao Y
Oxid Med Cell Longev; 2022; 2022():3192607. PubMed ID: 35757509
[TBL] [Abstract][Full Text] [Related]
35. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
36. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.
Zheng S; Wang J; Ding N; Chen W; Chen H; Xue M; Chen F; Ni J; Wang Z; Lin Z; Jiang H; Liu X; Wang L
J Nanobiotechnology; 2021 Nov; 19(1):381. PubMed ID: 34802453
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
[TBL] [Abstract][Full Text] [Related]
38. Targeting DNA Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate STING Pathway for Maximizing Chemo-Immunotherapy in Bladder Cancer.
Wang W; Yang F; Zhang L; Wang M; Yin L; Dong X; Xiao H; Xing N
Adv Mater; 2024 Jan; 36(1):e2308762. PubMed ID: 37849029
[TBL] [Abstract][Full Text] [Related]
39. RGD peptide modified platinum nanozyme Co-loaded glutathione-responsive prodrug nanoparticles for enhanced chemo-photodynamic bladder cancer therapy.
Hao Y; Chen Y; He X; Han R; Yang C; Liu T; Yang Y; Liu Q; Qian Z
Biomaterials; 2023 Feb; 293():121975. PubMed ID: 36580720
[TBL] [Abstract][Full Text] [Related]
40. A tumor microenvironment responsive nanoplatform with oxidative stress amplification for effective MRI-based visual tumor ferroptosis.
Luo S; Ma D; Wei R; Yao W; Pang X; Wang Y; Xu X; Wei X; Guo Y; Jiang X; Yuan Y; Yang R
Acta Biomater; 2022 Jan; 138():518-527. PubMed ID: 34775124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
